KR102714760B1 - Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 - Google Patents

Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 Download PDF

Info

Publication number
KR102714760B1
KR102714760B1 KR1020247004922A KR20247004922A KR102714760B1 KR 102714760 B1 KR102714760 B1 KR 102714760B1 KR 1020247004922 A KR1020247004922 A KR 1020247004922A KR 20247004922 A KR20247004922 A KR 20247004922A KR 102714760 B1 KR102714760 B1 KR 102714760B1
Authority
KR
South Korea
Prior art keywords
vwf
amino acids
domain
fviii
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247004922A
Other languages
English (en)
Korean (ko)
Other versions
KR20240023705A (ko
KR102714760B9 (ko
Inventor
엑타 세스 차브라
존 쿨맨
통야오 리우
Original Assignee
바이오버라티브 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52142742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102714760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오버라티브 테라퓨틱스 인크. filed Critical 바이오버라티브 테라퓨틱스 인크.
Priority to KR1020247032926A priority Critical patent/KR102865153B1/ko
Publication of KR20240023705A publication Critical patent/KR20240023705A/ko
Application granted granted Critical
Publication of KR102714760B1 publication Critical patent/KR102714760B1/ko
Publication of KR102714760B9 publication Critical patent/KR102714760B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247004922A 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 Active KR102714760B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247032926A KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
US61/840,872 2013-06-28
PCT/US2014/044731 WO2014210558A1 (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof
KR1020227045978A KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045978A Division KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032926A Division KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Publications (3)

Publication Number Publication Date
KR20240023705A KR20240023705A (ko) 2024-02-22
KR102714760B1 true KR102714760B1 (ko) 2024-10-11
KR102714760B9 KR102714760B9 (ko) 2025-09-15

Family

ID=52142742

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247004922A Active KR102714760B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020157033268A Active KR102666819B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020227045978A Ceased KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020247032926A Active KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020157033268A Active KR102666819B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020227045978A Ceased KR20230007555A (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR1020247032926A Active KR102865153B1 (ko) 2013-06-28 2014-06-27 Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Country Status (17)

Country Link
US (3) US20160251408A1 (enExample)
EP (2) EP3013358A4 (enExample)
JP (5) JP2016523919A (enExample)
KR (4) KR102714760B1 (enExample)
CN (3) CN113831415A (enExample)
AU (3) AU2014302100B2 (enExample)
CA (1) CA2913078A1 (enExample)
CL (1) CL2015003710A1 (enExample)
EA (1) EA201592022A1 (enExample)
HK (1) HK1223302A1 (enExample)
IL (3) IL297611B2 (enExample)
MX (1) MX2015016567A (enExample)
NZ (1) NZ713904A (enExample)
PH (1) PH12015502614A1 (enExample)
SG (3) SG10201913738YA (enExample)
TW (3) TWI844042B (enExample)
WO (1) WO2014210558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN110054699A (zh) * 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
DK3265489T3 (da) * 2015-03-06 2019-07-15 CSL Behring Lengnau AG Forbindelser til forbedring af halveringstiden af von willebrand faktor
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
JP6877469B2 (ja) * 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
KR20190085021A (ko) * 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146782A1 (en) 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
US20110183907A1 (en) 2008-06-24 2011-07-28 Thomas Weimer Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US20150266943A1 (en) 2012-07-11 2015-09-24 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
ATE313554T1 (de) 2000-05-16 2006-01-15 Lipoxen Technologies Ltd Derivatisierung von proteinen in wässrigem lösungsmittel
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
WO2003077834A2 (en) 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CA2663352A1 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN108530543B (zh) * 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
DK2440241T3 (en) 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP5544219B2 (ja) * 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
KR101808751B1 (ko) * 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US20110312881A1 (en) * 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
WO2013083858A1 (en) * 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
SG11201605242YA (en) * 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
SI3793588T1 (sl) * 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146782A1 (en) 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
US20110183907A1 (en) 2008-06-24 2011-07-28 Thomas Weimer Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
US20150266943A1 (en) 2012-07-11 2015-09-24 Amunix Operating Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Biotech., Vol. 27, No. 12, pp.1186-1190 (2009. 11. 15.)

Also Published As

Publication number Publication date
KR20240023705A (ko) 2024-02-22
KR102865153B1 (ko) 2025-09-29
IL266462B2 (en) 2023-04-01
AU2014302100B2 (en) 2020-02-13
EP4368194A2 (en) 2024-05-15
JP2022000053A (ja) 2022-01-04
EP3013358A4 (en) 2017-03-22
KR102666819B1 (ko) 2024-05-23
KR20160023654A (ko) 2016-03-03
TW201514204A (zh) 2015-04-16
IL242436B (en) 2019-05-30
KR20240148954A (ko) 2024-10-11
JP2019010124A (ja) 2019-01-24
SG10201913738YA (en) 2020-03-30
KR20230007555A (ko) 2023-01-12
JP7297837B2 (ja) 2023-06-26
US20240083975A1 (en) 2024-03-14
CN113831415A (zh) 2021-12-24
PH12015502614A1 (en) 2016-02-29
AU2020203063B2 (en) 2023-05-25
TW202313672A (zh) 2023-04-01
JP7623426B2 (ja) 2025-01-28
CA2913078A1 (en) 2014-12-31
SG11201509313PA (en) 2016-01-28
TWI844042B (zh) 2024-06-01
JP7005800B2 (ja) 2022-02-10
IL266462B (en) 2022-12-01
AU2020203063A1 (en) 2020-05-28
TW202045535A (zh) 2020-12-16
AU2014302100A1 (en) 2015-11-26
KR102714760B9 (ko) 2025-09-15
JP2025061316A (ja) 2025-04-10
IL297611B1 (en) 2025-07-01
NZ713904A (en) 2022-02-25
IL297611A (en) 2022-12-01
SG10201710616XA (en) 2018-02-27
CN113817069A (zh) 2021-12-21
AU2023219840A1 (en) 2023-09-14
CN105392495A (zh) 2016-03-09
JP2016523919A (ja) 2016-08-12
MX2015016567A (es) 2016-03-31
US20220106383A1 (en) 2022-04-07
EA201592022A1 (ru) 2016-05-31
BR112015031194A2 (pt) 2017-09-19
HK1223302A1 (zh) 2017-07-28
IL266462A (en) 2019-06-30
WO2014210558A1 (en) 2014-12-31
TWI716340B (zh) 2021-01-21
JP2021072853A (ja) 2021-05-13
CL2015003710A1 (es) 2016-08-26
EP4368194A3 (en) 2024-07-31
JP2023107932A (ja) 2023-08-03
EP3013358A1 (en) 2016-05-04
IL297611B2 (en) 2025-11-01
TWI770467B (zh) 2022-07-11
US20160251408A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
KR102865153B1 (ko) Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
KR102914074B1 (ko) A형 혈우병의 치료 방법
KR102409250B1 (ko) 인자 viii 키메라 단백질 및 이들의 용도
KR102212098B1 (ko) 키메라 인자 viii 폴리펩티드들과 이의 용도
TW201542596A (zh) 凝血酶可裂解連接子
JP7861172B2 (ja) Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
EA041588B1 (ru) Расщепляемый тромбином линкер, содержащий xten, и его применение
EA051005B1 (ru) Расщепляемый тромбином линкер, содержащий xten, и его применение
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0202 (AS PROVIDED BY THE NATIONAL OFFICE)

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20250828

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 2714760

Appeal request date: 20250805

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2025105000073

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2025105000073; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CORRECTION

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20250915

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1027147600000

Gazette reference publication date: 20241011